Mechanisms of fungal resistance: An overview

Drugs

Volumn 62, Issue 7, 2002, Pages 1025-1040

  Balkis, Maher M ^a   Leidich, Steven D ^a   Mukherjee, Pranab K ^a   Ghannoum, Mahmoud A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BETA LACTAMASE INHIBITOR; CHLORAMPHENICOL; CYCLOHEXIMIDE; ERGOSTEROL; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; FLUOROURIDINE TRIPHOSPHATE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; MC 510027; MICAFUNGIN; SQUALENE; TERBINAFINE; UNCLASSIFIED DRUG; ZYMOSTEROL;

ANTIFUNGAL ACTIVITY; CELL WALL; DNA REPLICATION; DRUG ACCUMULATION; FUNGAL GENE; GENE MUTATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; REVIEW; STEROL METABOLISM;

EID: 0036094710     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262070-00004     Document Type: Review

References (102)

1. HIV pathogenesis
2. Nosocomial fungal infections: Old problems and new challenges
3. Hospital-acquired candidemia. The attributable mortality and excess length of stay
4. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997
5. National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990
6. Nosocomial blood stream infection in United States Hospitals: A three year analysis
7. Current and emerging azole antifungal agents
8. Antifungal Agents: Mode of action, mechanism of resistance and correlation of these mechanism with bacterial resistance
9. Azole antifungal agents: Emphasis on new triazoles
10. Antifungal susceptibility testing
11. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
12. Susceptibility testing of fungi: Current status of correlation of in vitro data with clinical outcome
13. Amphotericin B-resistant yeast infection in severely immunocompromised patients
14. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models
15. Utility of 2,3- Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenyl-amino) carbonyl]-2H- tetrazolium hydroxide(XTT) and minimum effective concentration assays in the determination of antifungal susceptibility of Aspergillus fumigatus to the lipopeptide class of compounds
16. Molecular mechanisms of antifungal agents associated with membrane ergosterol: Dysfunction of membrane ergosterol and inhibition of ergosterol biosynthesis
17. Mode of action and resistance to azole antifungals associated with the formation of 14α-methyl-ergosta-8,24(28)-dien- 3β,6α-diol
18. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Delta (5,6) desaturation
19. Ergosterol biosynthesis inhibitors
20. Interaction of azole antifungal antibiotics with cytochrome P450-dependent 14α-sterol demethylase purified from Candida albicans
21. Effect of the antimycotics, miconazole and ketoconazole on cytochrome P450 in yeast microsomes and rat liver microsomes
22. Biochemical effect of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans
23. Inhibition by ketoconazole of mitogen-induced DNA synthesis and cholesterol biosynthesis in lymphocytes
24. Pharmacological inhibition of intracellular transport of low-density lipoprotein-derived cholesterol in chinese hamster ovary cells
25. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis
26. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
27. The presence of an R467K amino acid substitution and loss of alleleic variation correlate with an azole-resistant lanosterol 14α-demethylase in Candida albicans
28. Molecular mechanisms of azole resistance in fungi
29. Clinical, cellular and molecular factors that contribute to antifungal drug resistance
30. The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinity
31. The mutation T315A in Candida albicans sterol 14 alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity
32. Aspergillus fumigatus CYP 51 sequence; potential basis for fluconazole resistance
33. Characterization of an azole-resistant Candida glabrata isolate
34. Deletion of the Candida glabrata ERG3 and ERG11 Genes: Effect on cell viability, cell growth, sterol composition, and antifungal susceptibility
35. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans
36. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata
37. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: Possible role for drug efflux in drug resistance
38. Cross-resistance to polyene and azole drugs in Cryptococcus neoformans
39. Itraconazole resistance in Aspergillus fumigatus
40. A complete catalogue of Saccharomyces cerevisiae ABC proteins and their relevance to human health and disease
41. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents
42. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata
43. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene
44. Multidrug resistance genes in Candida albicans
45. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals
46. Biochemistry of multidrug resistance mediated by the multidrug transporter
47. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
48. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance
49. AP1-mediated multidrug resistance in Saccharomyces cerevisiae requires FLR1 encoding a transporter of the major facilitator superfamily
50. Analysis of a Candida albicans gene that encodes a novel mechanism of resistance to benomyl and methotrexate
51. A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole
52. New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: Implications for antifungal azole resistance
53. In vivo selection of an azole-resistant petite mutant of Candida glabrata
54. Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14alpha-demethylase gene, pdmA
55. Sterol composition of itraconazole-resistant and itraconazole-susceptible isolates of Aspergillus fumigatus
56. Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agents
57. The polyene macrolide antifungal drugs
58. The effects of the polyene antibiotics nystatin and amphotericin B on thin lipid membranes
59. Polyene antibiotic-sterol interactions in membranes of Acholeplasma laidlawaii cells and lecithin liposomes. III. Molecular structure of the polyene antibiotic-cholesterol complexes
60. The plasma membrane of Candida albicans and its role in the action of antifungal drugs
61. The protoplast membrane and antifungal drugs
62. Resistance to antifungal agents in the critical care setting: Problems and perspectives
63. Chemistry and biology of the polyene macrolide antibiotics
64. Antimicrobial agents. XII. Relationship between biochemical resistance and microbial degradation of antimycotics
65. Incidence of polyene-resistant yeasts recovered from clinical specimens
66. Resistance to amphotericin B associated with defective sterol Δ8,7 isomerase in a Cryptococcus neoformans strain from an AIDS patient
67. Mechanism of action and biochemical selectivity of allylamine antimycotic agents
68. Lipid interactions in membranes of extremely halophilic bacteria. II. Modification of the bilayer structure by squalene
69. Antifungal activity and mechanism of action of terbinafine
70. Susceptibility of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
71. Compounds active against cell walls of medically important fungi
72. Lysis of growing yeast-form cells of Candida albicans by echinocandin: A cytological study
73. Glucan biosynthesis in fungi and its inhibition
74. The antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3β-glucan synthase inhibitor, during continuous and intermittent intravenous infusions of cilofungin in treatment of experimental disseminated candidiasis
75. Echinocandin B. Ein neuartiges polypeptide antibiotikum aus aspergillus nidulans varachinulatus: Isolierung und bausteine [in Dutch]
76. Antibiotics that inhibit fungal cell wall development
77. New antifungal drug targets: A vision for the future
78. Lipopeptide inhibitors of fungal glucan synthase
79. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-β-D-glucan synthase
80. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase
81. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans
82. Mechanisms and clinical impact of drug resistance
83. Anti-Candida drugs-the biochemical basis for their activity
84. Mode of action of 5-fluorocytosine
85. Mode of action of 5-fluorocytosine and mechanisms of resistance
86. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans
87. Human mycoses: Drugs and targets for emerging pathogens
88. Factors affecting the changes in amphotericin B sensitivity of Candida albicans during growth
89. An in vitro head-to-head comparison of Schering 5692, amphotericin B, fluconazole, and itraconazole against a spectrum of filamentous fungi
90. Epidemiology of human immunodeficiency virus: Associated opportunistic infections in the United States in the era of highly active antiretroviral therapy
91. Positive effect of combined antiretroviral therapy on CD4 T-cell homeostasis and function in advanced HIV disease
92. Improvement in cell-mediated immune functions during potent anti-human immunodeficiency virus therapy with ritonavir plus saquivir
93. High-dose therapy with fluconazole > or =800mg day-1
94. A strategy for fighting antibiotic resistance: Administering drugs to force pathogens into attaining two or more mutations to grow could restrict development of resistance
95. The exciting future of antifungal therapy
96. New investigational antifungal agents for treating invasive fungal infections
97. Impact of MC-510,027, a fungal efflux pump inhibitor, on the susceptibility of clinical isolates of Candida spp. to antifungal agents
98. Starting life resistance-free
99. Epidemiology of drug resistance: Implications for a post-antimicrobial era
100. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals